Maxim Group Starts CASI Pharmaceuticals (CASI) at Buy

September 21, 2016 5:27 PM EDT Send to a Friend
Maxim Group initiates coverage on CASI Pharmaceuticals (NASDAQ: CASI) with a Buy rating and a price target of $4.00.Analyst Gabrielle ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login